
|Articles|July 1, 1999
Supplements and Featured Publications
- Evaluating the Health Benefits of Atypical Agents in the Treatment and Management of Psychoses
- Volume 5
- Issue 10 Suppl
Introduction
Advertisement
Articles in this issue
over 26 years ago
Participating Facultyover 26 years ago
Assessment of Quality-of-Life Outcomes in Schizophrenic Patientsover 26 years ago
The Emerging Role of Psychiatric Pharmacistsover 26 years ago
CME/CE Quizover 26 years ago
Selected Abstractsover 26 years ago
BibliographyNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
'Tis the Season: SABCS 2025 to Highlight Latest Advances Across the Breast Cancer Continuum
2
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
3
Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML
4
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
5














































